TEAD4: A Promising Drug Target and Biomarker for ALS-Like conditions

Target Name: TEAD4

NCBI ID: G7004

TEAD4

TEAD4: A Promising Drug Target and Biomarker for ALS-Like conditions

Introduction

Autophagy is a crucial intracellular waste management mechanism that helps maintain cellular health and longevity. However, when this process goes awry, it can lead to a wide range of disorders, including ALS-like conditions. Transcriptional enhancer factor 3 (TEAD4) is a key regulator of autophagy and has been linked to various neurological disorders. In this article, we will explore TEAD4 as a drug target and biomarker for ALS-like conditions.

The Importance of Autophagy in Health and Disease

Autophagy is a complex cellular process that involves the breaking down of intracellular organelles, including mitochondria, into their constituent parts. This process is essential for maintaining cellular health and longevity, as damaged or dysfunctional cells can no longer function properly. Autophagy also plays a key role in the regulation of cellular waste, ensuring that harmful substances are removed from the body.

However, when autophagy fails to function correctly, it can lead to a wide range of disorders, including ALS-like conditions. ALS (Amyotrophic Lateral Sclerosis) is a progressive neurodegenerative disorder that is characterized by the progressive loss of motor neurons. The exact cause of ALS is not known, but it is thought to involve the dysfunction of autophagy, which leads to the build-up of harmful substances in the brain.

TEAD4: A Key Regulator of Autophagy

TEAD4 is a protein that was discovered as a key regulator of autophagy. It is a transcription factor, which means it works by binding to specific DNA sequences to regulate gene expression. TEAD4 has been shown to play a crucial role in the regulation of autophagy by interacting with the proteinBeclin-1 (BECN1).

TEAD4 regulates autophagy by recruitingBeclin-1 to its downstream target, the proteinBeclin-3 (BECL3).Beclin-1 and Beclin-3 are part of a protein complex that is involved in the regulation of autophagy. TEAD4 has been shown to physically interact with Beclin-1 and Beclin-3, leading to the recruitment of these proteins to its downstream target.

In addition to its role in autophagy, TEAD4 has also been shown to play a role in cell survival and proliferation. It has been shown to promote the survival of cancer cells and to contribute to the regulation of cell proliferation.

Drug Targeting and Biomarker for ALS-Like Conditions

The dysfunction of autophagy, as seen in ALS, can be treated with drugs that target TEAD4. One such drug is baclofen, which is a muscle relaxant that works by blocking the action of a protein called GABA. Baclofen has been shown to be effective in treating ALS-like conditions by restoring autophagy in the affected muscles.

Another drug that has been shown to target TEAD4 is riatropin, which is a drug used to treat ALS. Riatropin works by inhibiting the action of a protein called TP53, which is a key regulator of DNA damage. By inhibiting TP53, riatropin allows for the proper regulation of autophagy and the removal of damaged cellular waste.

Biomarkers for ALS-Like Conditions

The dysfunction of autophagy, as seen in ALS, can be monitored using various biomarkers. One such biomarker is the proteinSirT1, which is a natural antioxidant that is involved in

Protein Name: TEA Domain Transcription Factor 4

Functions: Transcription factor which plays a key role in the Hippo signaling pathway, a pathway involved in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Acts by mediating gene expression of YAP1 and WWTR1/TAZ, thereby regulating cell proliferation, migration and epithelial mesenchymal transition (EMT) induction. Binds specifically and non-cooperatively to the Sph and GT-IIC 'enhansons' (5'-GTGGAATGT-3') and activates transcription. Binds to the M-CAT motif

The "TEAD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TEAD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets